18 / 31
Study Endpoints
•Primary-Time to Metastatic Disease
or Death (TMDD)
•Secondary-PFS, OS, and Toxicity
ClinicalTrials.gov Identifier: NCT02343952
|
|
18 / 31
18 / 31
Study Endpoints
•Primary-Time to Metastatic Disease
or Death (TMDD)
•Secondary-PFS, OS, and Toxicity
ClinicalTrials.gov Identifier: NCT02343952